BioSpace News Archive

PureTech Health plc announced that Daphne Zohar, founder and chief executive officer, will present at the 19th Annual Virtual Needham Healthcare Conference on Wednesday, April 15, at 1:30 PM EDT.

Harvard Chan School-Human Vaccines Project collaboration will use artificial intelligence and causal inference to accelerate drug and vaccine development

Post Acute Medical, which operates over 40 post-acute specialty hospitals across the country, has agreed to enable Cura Telehealth, a national telemedicine company, to use its properties to improve COVID-19 testing availability to the public during this time of high demand.

New Implantable Neurostimulator Decreases Recharge Interval to Only Once a Month

BriaCell Therapeutics Corp. announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office outlining certain features thought to expand the clinical applications of BriaCell’s genetically engineered whole-cell immunotherapies to those of infectious diseases including the SARS-CoV-2 virus that causes Coronavirus Disease 2019.

Johnson & Johnson announced that its Board of Directors has declared a 6.3% increase in the quarterly dividend rate, from $0.95 per share to $1.01 per share.

Calithera Biosciences, Inc., a clinical stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, shared an update on business operations, including clinical program adjustments related to COVID-19.

Sales of $20.7 billion reflecting strong growth of 3.3%, operational growth of 4.8%* and adjusted operational growth of 5.6%*, inclusive of the overall estimated negative impact of the COVID-19 pandemic

Compugen Ltd. announced that it will present updates on its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, for the treatment of advanced solid tumors in an oral presentation at the 2020 American Association for Cancer Research Virtual Annual Meeting I on April 27, 2020 at 11:45 AM EST.

OpGen, Inc. announced that total revenue for the first quarter of 2020 was approximately $617,000 down from $1.0 million in the first quarter of 2019, excluding revenues from the Curetis businesses, which was acquired upon closing of the business combination on April 1, 2020.